X-Chem has been leading the DNA-encoded library (DEL) field for more than a decade. We have delivered over 90 programs to our partners and clients, comprising over 1,000 novel, validated hit compounds across more than 30 different target classes. Most of these projects are actively progressed by our clients and remain confidential, but examples have been published in peer-reviewed journals. We have compiled these examples into the list below: They span a wide variety of therapy areas and target classes. Some represent our older and more peptidic libraries and others exemplify more contemporary and lead-like library designs. We continue to be at the forefront of DEL development, incorporating AI in drug discovery to explore greater chemical space.

Click below to take a tour through X-Chem’s track record of success.

Published Successes From X-Chem and Our Partners

Enzymes
Target: LpxA Inhibitor, IC50= 19 nM
Therapy Area: Infectious Disease
Enzymes
Target: HAO1 Inhibitor, IC50= 25 nM
Therapy Area: Rare Disease
Receptors
Target: ERa Binder, IC50= 50 nM
Therapy Area: Oncology
Receptors
Target: PAR2 Antagonist, IC50= 23 nM
Therapy Area: Neurology
Receptors
Target: PAR2 Antagonist, EC50= 230 nM
Therapy Area: Neurology
Enzymes
Target: ATX Inhibitor, IC50= 55 nM
Therapy Area: Inflammation
Kinases
Target: TAK1 Inhibitor, IC50= 5 nM
Therapy Area: Oncology
Enzymes
Target: sEH Inhibitor, IC50= 2 nM
Therapy Area: Inflammation
Kinases
Target: BTK Inhibitor, IC50= 2 nM
Therapy Area: Oncology
Kinases
Target: BTK Inhibitor, IC50= 60 nM (1h)
Therapy Area: Oncology
Kinases
Target: MerTK Inhibitor, IC50= 5 nM
Therapy Area: Oncology
Enzymes
Target: KMO Inhibitor, IC50= 14 nM
Therapy Area: Oncology
Protein Protein Interaction
Target: ATAD2 Inhibitor, IC50= 25 nM
Therapy Area: Oncology
Protein Protein Interaction
Target: Mcl-1 Inhibitor, IC50= <3 nM
Therapy Area: Oncology
Enzymes
Target: InhA Inhibitor, IC50 = 26 nM
Therapy Area: Tuberculosis